Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment

Yang, Jiezuan; Dong, Yan; Guo, Renyong; Chen, Jiajia; Li, Yongtao; Fan, Jun; Fu, Xin; Yao, Xin‐Sheng; Diao, Hongyan; Li, Lanjuan

doi:10.1097/md.0000000000006242

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several serum markers, such as HBV DNA, quantitative HBsAg, and alanine aminotransferase (ALT), have been identified as predictors of Peg-IFN or NUC treatment outcome in the early treatment stage (Martinot-Peignoux et al, 2013;Yang et al, 2017). Recently, serum HBV RNA was proposed as a useful viral marker for CHB during therapy (Gao et al, 2017;Giersch et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

Wang

Chi

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Background: In some previous studies, serum hepatitis B virus RNA (HBV RNA) was proposed as an HBV viral marker during therapy. However, the dynamic change of HBV RNA, the correlation of HBV RNA with cccDNA, and the combination of HBV RNA with known HBV markers in predicting entecavir (ETV) treatment outcome in the same cohort are rarely reported. Methods: A total of 111 HBeAg-positive patients were enrolled in our study. The dynamic changes of serum HBV RNA and the correlation of HBV RNA with other HBV markers were investigated in the early treatment period of 144-week ETV treatment. Intrahepatic cccDNA was detected at baseline and week 48. Receiver operating characteristic analyses were used to identify HBV RNA levels associated with HBeAg seroconversion. Results: The serum HBV RNA levels decreased more rapidly in patients with HBeAg seroconversion than those without HBeAg seroconversion. The levels of HBV RNA decreased slower compared with the serum HBV DNA, irrespective of whether the patients achieved HBeAg seroconversion or not. Although the serum HBV RNA was positively correlated with cccDNA at baseline among all patients, no significant correlation was observed in the patients with HBeAg seroconversion at week 48 (r = 0.094, P = 0.588). The area under the receiver operating characteristic (AUROC) of HBV RNA and HBeAg at week 24 was 0.754 and 0.800, respectively. The AUROC of the HBV RNA and HBeAg combination had a higher value

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

Wang

Chi

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In detail, all subjects were orally treated with 300 mg of TDF-naive daily and were scheduled to continue the TDF treatment for 96 weeks. The twenty HBeAg (+) CHB subjects were divided into HBeAg seroconverting (SC, n = 9) or non-SC ( n = 11) groups, depending on whether they had undergone HBeAg SC by week 72 of TDF treatment, that was HBeAg loss (quantitative HBeAg < 0.18 PEIU/mL) and positive for anti-HBe antibody (quantitative anti-HBe < 1.00 S/CO) [ 20 ]. This protocol was approved by the ethics committee of the FHZJU (Reference No.…”

Section: Methodsmentioning

confidence: 99%

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment

Yang

Lü

Chen

et al. 2023

Journal of Immunology Research

Self Cite

View full text Add to dashboard Cite

Background. It is lacking that markers could predict the prognosis of chronic hepatitis B (CHB) subjects during antiviral treatment, and the related cellular immune mechanism is not fully evaluated. Aim. To explore the comprehensive profile of T cell receptor β-chain (TRBV) and CD4+CD25+ regulatory T cell (Treg) in peripheral blood of CHB patients with HBeAg seroconverting (SC) during tenofovir disoproxil fumarate (TDF) treatment. Methods. The frequency of CD4+CD25high+ Treg and number of skewed TRBV in 20 HBeAg positive patients were determined at baseline and following every 12 weeks during 96-week TDF treatment. The relationship among serum alanine aminotransferase (ALT) level, HBV DNA load, Treg frequency, and the number of skewed TRBV, respectively, was analyzed for CHB patients. Receiver operative characteristic curve was applied to analyze their diagnostic value for HBeAg SC. Results. The number of skewed TRBV at week 48, Treg frequency at week 72, and ALT level at baseline could predict the HBeAg SC or non-SC in CHB patients during 96-week TDF treatment. Moreover, the positive correlation between ALT or HBV DNA and Treg levels or skewed TRBVs was significant in the SC group, but not in non-SC. Conclusions. The predictive cutoff value of ALT for HBeAg SC was 178 U/L at baseline. Moreover, the ALT, Treg, and TRBV families would be associated with the prognosis and pathogenesis of CHB patients during TDF treatment.

show abstract

“…BV12, BV15, and BV22 were predominant in the patients who had not seroconverted. In addition to the Treg frequency and alanine aminotransferase (ALT) level, the Treg profile and TRBVs were associated with HBeAg seroconversion and may be potential predictors of HBeAg seroconversion and treatment outcome in CHB patients[ 55 , 56 ]. A recent TCR repertoire study by Lian et al [ 57 ] in 20 CHB patients undergoing 1-year ETV treatment found that the diversity of TCRβ repertoires was decreased in the 10 HBeAg- seroconverted patients but increased in the 10 patients without HBeAg seroconversion.…”

Section: Application Of Immune Repertoire Analysis In Hbv Therapymentioning

confidence: 99%

Human immune repertoire in hepatitis B virus infection

Zhan¹,

Xu²,

Yu³

et al. 2021

WJG

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a public health threat that affects 257 million people worldwide and can progress to liver cirrhosis, liver failure, and hepatocellular carcinoma. The HBV antigen- induced adaptive immune response plays an important role in HBV clearance. Immune repertoire sequencing (IRS) has been used to investigate the molecular mechanisms behind the immune system, find novel ways to treat HBV infection, and evaluate the genetic responses and immune characteristics of individuals infected by HBV or immunized by HBV vaccine. This review summarizes the human immune repertoire analysis methodology, and the application of the IRS in the prediction of HBV infection progression, treatment, and vaccination.

show abstract

Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment

Abstract: Supplemental Digital Content is available in the text

Cited by 3 publications

References 36 publications

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment

Human immune repertoire in hepatitis B virus infection

Contact Info

Product

Resources

About